{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:54:42Z","timestamp":1720583682204},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"\u201cChinese National Major Project for New Drugs Innovation\u201d","award":["2008ZX09312, 2012ZX09303012-001"],"award-info":[{"award-number":["2008ZX09312, 2012ZX09303012-001"]}]},{"name":"Beijing Municipal Science and Technology Commission Major Project for New Drug Innovation","award":["Z121102009212055"],"award-info":[{"award-number":["Z121102009212055"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jchromb.2016.04.050","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T16:22:10Z","timestamp":1462551730000},"page":"119-125","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of a UHPLC\u2013MS\/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients"],"prefix":"10.1016","volume":"1025","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2016.04.050_bib0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3322\/caac.20102","article-title":"Lung cancer: new biological insights and recent therapeutic advances","volume":"61","author":"Ramalingam","year":"2011","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 17","key":"10.1016\/j.jchromb.2016.04.050_bib0015","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1002\/cncr.29584","article-title":"Prevention and management of lung cancer in China","volume":"121","author":"Hong","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jchromb.2016.04.050_bib0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/1759-7714.12218","article-title":"Current small cell lung cancer treatment in China","volume":"6","author":"Shi","year":"2015","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.jchromb.2016.04.050_bib0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","article-title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised double-blind phase 3 non-inferiority trial","volume":"14","author":"Shi","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0030","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0035","first-page":"77","article-title":"Chemotherapy: continued lack of progress in SCLC, Nature reviews","volume":"7","author":"Subramanian","year":"2010","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0040","first-page":"5","article-title":"The role of anthracyclines in small cell lung cancer","volume":"1","author":"Lopez-Gonzalez","year":"2013","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jnci\/89.16.1217","article-title":"Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo","volume":"89","author":"Arcamone","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0050","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002800100350","article-title":"Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours","volume":"48","author":"Bos","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdf061","article-title":"Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer Early Clinical Studies Group","volume":"13","author":"Schrijvers","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-2952(01)00645-1","article-title":"A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue","volume":"62","author":"Bigioni","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0065","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00005344-200001000-00013","article-title":"Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat","volume":"35","author":"Cirillo","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0070","series-title":"Guidance for Industry, Bioanalytical Method Validation","year":"2001"},{"key":"10.1016\/j.jchromb.2016.04.050_bib0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1039\/B805160G","article-title":"Investigation of the matrix effects on a HPLC\u2013ESI-MS\/MS method and application for monitoring triazine, phenylurea and chloroacetanilide concentrations in fresh and estuarine waters","volume":"11","author":"Mazzella","year":"2009","journal-title":"J. Environ. Monit."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0080","series-title":"Committee for Medicinal Products for Human Use (CHMP), Guideline on Bioanalytical Method Validation","year":"2011"},{"issue":"Suppl. 4","key":"10.1016\/j.jchromb.2016.04.050_bib0085","first-page":"1170","article-title":"Phase I and pharmacokinetic study of MEN-10755 in solid tumors(abstract)","volume":"35","author":"Bos","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jchromb.2016.04.050_bib0090","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0959-8049(99)81581-0","article-title":"Phase I study to determine the safety of MEN-10755 in patients with a solid tumor on a short i.v. infusion given once every 3 weeks(abstract)","volume":"35","author":"Roelvink","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.jchromb.2016.04.050_bib0095","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","article-title":"Anthracycline cardiotoxicity","volume":"11","author":"Menna","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014a report from the Children's Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jchromb.2016.04.050_bib0105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1021\/tx000143z","article-title":"Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite","volume":"13","author":"Minotti","year":"2000","journal-title":"Chem. Res. Toxicol."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216302896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023216302896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T05:22:30Z","timestamp":1536729750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023216302896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":21,"alternative-id":["S1570023216302896"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.04.050","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a UHPLC\u2013MS\/MS method for simultaneous quantitation the plasma concentration of Sabarubicin and its alcohol metabolite M3 in Chinese small cell lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2016.04.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}